Literature DB >> 18498029

Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor.

Fumiyo Higaki1, Yoshihiro Okumura, Shuhei Sato, Takao Hiraki, Hideo Gobara, Hidefumi Mimura, Shiro Akaki, Toshihide Tsuda, Susumu Kanazawa.   

Abstract

OBJECTIVE: The aim of this study was to clarify the most appropriate follow-up initiation time point for positron emission tomography (PET)/computed tomography (CT) following radio frequency ablation (RFA) of lung tumors, and the cutoff values of maximum standard uptake value (SUV(max)) to evaluate local tumor progression.
METHODS: We enrolled 15 patients (8 men, median age 62 years) with 60 tumors, who were treated with RFA of lung tumors and underwent fluorodeoxyglucose (FDG)-PET/CT following RFA. Local tumor progression was assessed by periodic chest CT images prior to and following intravenous administration of a contrast medium. The SUV(max) of three periods, namely, 0-3 months, 3-6 months, and 6-9 months after RFA, was evaluated. The appropriate time point for follow-up initiation and the cutoff value of SUV(max) were determined using receiver-operating characteristic (ROC) analysis.
RESULTS: The median follow-up period was 357 days. Of 60 tumors, 10 showed local progression. The area under the ROC curve (Az) for the 6-9 months (P = 0.044) was the largest and almost equal to that of the 3-6 months (P = 0.024). Az for the 0-3 months was the smallest and statistically insignificant (P = 0.705). The cutoff value of 1.5 of SUV(max) at 3-9 months after RFA showed 77.8% sensitivity and 85.7-90.5% specificity.
CONCLUSIONS: The appropriate follow-up initiation time point is at least 3 months following RFA. Thus, SUV(max) is a useful and reliable predictive indicator.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498029     DOI: 10.1007/s12149-007-0113-0

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  17 in total

1.  Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.

Authors:  Françoise Bonichon; Jean Palussière; Yann Godbert; Marina Pulido; Edouard Descat; Anne Devillers; Catherine Meunier; Sophie Leboulleux; Thierry de Baère; Claire Galy-Lacour; Laurent Lagoarde-Segot; Anne-Laure Cazeau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-17       Impact factor: 9.236

2.  A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.

Authors:  Mitsunori Higuchi; Hiroshi Honjo; Takeshi Shigihara; Fumio Shishido; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-21       Impact factor: 4.553

Review 3.  Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances.

Authors:  S L Smith; P E Jennings
Journal:  Br J Radiol       Date:  2014-12-03       Impact factor: 3.039

4.  Case report: Positron emission tomography fails to detect pulmonary adenocarcinoma recurrence after radiofrequency ablation.

Authors:  Cara Odenthal; Karin Steinke
Journal:  J Radiol Case Rep       Date:  2013-11-01

5.  A synthetic tryptophan metabolite reduces hemorrhagic area and inflammation after pulmonary radiofrequency ablation in rabbit nonneoplastic lungs.

Authors:  Hiroshi Nakada; Atsushi Yamashita; Masaomi Kuroki; Eiji Furukoji; Noriko Uchino; Taketoshi Asanuma; Yujiro Asada; Shozo Tamura
Journal:  Jpn J Radiol       Date:  2014-01-22       Impact factor: 2.374

Review 6.  Radiofrequency ablation of lung tumors: imaging features of the postablation zone.

Authors:  Fereidoun G Abtin; Jilbert Eradat; Antonio J Gutierrez; Christopher Lee; Michael C Fishbein; Robert D Suh
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

7.  Utilizing gemstone spectral CT imaging to evaluate the therapeutic efficacy of radiofrequency ablation in lung cancer.

Authors:  Lei Liu; Xiuyi Zhi; Baodong Liu; Yi Zhang
Journal:  Radiol Med       Date:  2015-11-27       Impact factor: 3.469

8.  Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol.

Authors:  Ying Wang; Guodong Li; Wentao Li; Xinhong He; Lichao Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702).

Authors:  Hideo Gobara; Yasuaki Arai; Takeshi Kobayashi; Koichiro Yamakado; Yoshitaka Inaba; Yoshihisa Kodama; Takuji Yamagami; Miyuki Sone; Hirokazu Watanabe; Yoshihiro Okumura; Takayoshi Shinya; Hiroaki Kurihara; Susumu Kanazawa
Journal:  Jpn J Radiol       Date:  2016-06-03       Impact factor: 2.374

10.  Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study.

Authors:  T Okuma; T Matsuoka; A Yamamoto; S Hamamoto; K Nakamura; Y Inoue
Journal:  Br J Radiol       Date:  2009-05-26       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.